



FOR IMMEDIATE RELEASE

## Veeva Introduces Link Workflow, a No-Code Platform for Building Custom Workflow Applications

*Business users can now easily build compliant workflow applications on Veeva Link data*

**BARCELONA, Spain — 3 May 2023 — 2023 Veeva Commercial Summit, North America — Veeva Systems** (NYSE: VEEV) today announced the availability of **Veeva Link Workflow**, a no-code platform to build custom workflow applications on Veeva Link real-time data.

Process owners can easily define workflows with objectives, events, and tasks on Link data including key opinion leaders, and key accounts. Reports and dashboards provide process visibility while granular security and audit trails assure control and compliance.

“Many critical processes in life sciences live outside of established application boundaries and are managed in spreadsheets and email,” said Kilian Weiss, general manager of Veeva Link. “Link Workflow provides a foundation to drive more organized and connected execution across clinical and commercial.”

Veeva Link is a family of connected data applications for real-time intelligence that includes Link Key People, Link Key Accounts, Link Scientific Awareness, and Link Medical Insights. Customers can build custom workflows on Link data using the Link Workflow no-code platform.

Link is a part of **Veeva Commercial Cloud**, a family of software, data, and services to advance commercial excellence in life sciences. Veeva also announced significant innovations across Commercial Cloud including **Vault CRM**, the next generation of CRM including new CRM Bot and Service Center applications.

### Additional Information

For more on Veeva Link, visit: [veeva.com/eu/Link](https://veeva.com/eu/Link)

Connect with Veeva on LinkedIn: [linkedin.com/company/veeva-systems](https://linkedin.com/company/veeva-systems)

### About Veeva Systems

Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest biopharmaceutical companies to emerging biotechs. As a **Public Benefit Corporation**, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit [veeva.com/eu](https://veeva.com/eu).

### Veeva Forward-looking Statements

This release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2023, which you can find [here](#) (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at [sec.gov](https://sec.gov).

###

**Contact:**

Jeremy Whittaker  
Veeva Systems  
+49-695-095-5486  
[jeremy.whittaker@veeva.com](mailto:jeremy.whittaker@veeva.com)